Financial

Cagent Vascular Reports First Human Use of Serranator® SONIC IVL System and Closes Oversubscribed $41M Series D Financing

Share by Ken Dropiewski on

More in Financial:

Share this story

WAYNE, Pa.–(BUSINESS WIRE)– #CLI–Cagent Vascular, Inc. announces completion of first human-use cases with the Serranator SONIC IVL System and closing of $41 million Series D round.

See full post here as originally published on this site

Ken has been in the cardiac, vascular, and interventional space for over 20 years. He is a Partner with McDermott + Bull Executive Search, recognized by Forbes as one of the industry's best with offices across North America and in Europe. Ken is hired by innovative cardiovascular device and biotech companies to help build their best teams possible at the executive level. Prior to search, Ken had an award winning commercial career at Boston Scientific and Johnson & Johnson to include such prestigious awards as President's Club, Ring Club, and Grand Awards. dropiewski@mbexec.com

Leave a Comment

Your email address will not be published. Required fields are marked *

*